FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...
Chocolate Recall Update As FDA Sets Highest Risk Level for 9 States
A recall which was issued across nine states has now been given the highest risk classification by the federal agency.
Trump admin's FDA withdraws proposed federal rule to ban menthol cigarettes
Trump's FDA moved to squash a proposed rule to ban menthol cigarettes just one day after the president was sworn in, angering ...
Did RFK Jr.’s Lawyer Ask the FDA to Revoke Approval for the Polio Vaccine?
Aaron Siri, a lawyer advising Robert F. Kennedy Jr. as he prepared to become health secretary, petitioned the Food and Drug ...
Broccoli Recall Update as FDA Sets Highest Risk Level Over Bacteria Fears
Broccoli florets sold in Walmart stores across 20 states that were recalled over bacterial contamination fears have been ...
US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...
Lay’s potato chip recall elevated to FDA’s highest-risk classification
The FDA has upgraded a recall of Lay’s Potato Chips to the highest level possible, meaning consuming the chips will cause ...
Becker's Hospital Review53m
FDA warns GLP-1 compounder over safety rules
The FDA issued a warning letter to ProRx, a compounding facility in Exton, Penn., after an inspection raised serious concerns regarding the safety and compliance of its drug products. The facility, ...
FDA approves Ozempic to help reduce risk of worsening chronic kidney disease
The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...
FDA Approves Ozempic to Treat Kidney Disease
The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...
R Street Institute1hOpinion
Trump: Look at the Slow-Moving FDA
The Food and Drug Administration’s approval of low-risk tobacco pouches is welcome, but why did it delay for more than four ...